
    
      The aim of the present trial is to assess the efficacy of the standalone use of SeQuent(R)
      Please coated balloon compared to a bare metal stent (BMS) in patients with NSTEMI. Primary
      efficacy endpoint will be MACE (cardiac mortality, reinfarction, and target lesion
      revascularization) after 9 months.
    
  